212 related articles for article (PubMed ID: 16644400)
1. Therapeutic goals in Gaucher disease.
Mistry P; Germain DP
Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic objectives in Gaucher disease].
Mistry P; Germain DP
Rev Med Interne; 2007 Oct; 28 Suppl 2():S171-5. PubMed ID: 18228683
[TBL] [Abstract][Full Text] [Related]
3. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Hachulla E; Javier RM
Rev Med Interne; 2007 Oct; 28 Suppl 2():S180-2. PubMed ID: 18228685
[No Abstract] [Full Text] [Related]
4. [Clinical study of the French cohort of Gaucher disease patients].
Stirnemann J
Rev Med Interne; 2006 Mar; 27 Suppl 1():S18-21. PubMed ID: 16644396
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Gaucher's disease with OGT 918.
Mistry PK
Lancet; 2000 Aug; 356(9230):676-7. PubMed ID: 10968454
[No Abstract] [Full Text] [Related]
6. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
[TBL] [Abstract][Full Text] [Related]
7. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
Camou F; Viallard JF
Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
[No Abstract] [Full Text] [Related]
8. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
Grigorescu Sido P; Drugan C; Cret V; Al-Kzouz C; Denes C; Coldea C; Zimmermann A
J Inherit Metab Dis; 2007 Oct; 30(5):783-9. PubMed ID: 17703370
[TBL] [Abstract][Full Text] [Related]
9. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
10. Gaucher disease: hematologic and oncologic implications.
Hughes D
Clin Adv Hematol Oncol; 2011 Oct; 9(10):771-2. PubMed ID: 22252578
[No Abstract] [Full Text] [Related]
11. Gaucher disease: unmet treatment needs.
Mehta A
Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
[TBL] [Abstract][Full Text] [Related]
12. [Current development and usefulness of biomarkers for Gaucher disease follow up].
Maire I; Guffon N; Froissart R
Rev Med Interne; 2007 Oct; 28 Suppl 2():S187-92. PubMed ID: 18228687
[TBL] [Abstract][Full Text] [Related]
13. Individualization of long-term enzyme replacement therapy for Gaucher disease.
Andersson HC; Charrow J; Kaplan P; Mistry P; Pastores GM; Prakash-Cheng A; Rosenbloom BE; Scott CR; Wappner RS; Weinreb NJ;
Genet Med; 2005 Feb; 7(2):105-10. PubMed ID: 15714077
[TBL] [Abstract][Full Text] [Related]
14. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
[No Abstract] [Full Text] [Related]
15. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Javier RM; Hachulla E
Presse Med; 2007 Dec; 36(12 Pt 3):1971-84. PubMed ID: 17498916
[TBL] [Abstract][Full Text] [Related]
16. [Cost reduction in the treatment of Gaucher s disease].
García Salom P; Acedo A
Farm Hosp; 2007; 31(3):194-5. PubMed ID: 17941761
[No Abstract] [Full Text] [Related]
17. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
[TBL] [Abstract][Full Text] [Related]
18. [New data on Gaucher's disease].
Stirnemann J
Rev Med Interne; 2008 Mar; 29(3):176-8. PubMed ID: 17964006
[No Abstract] [Full Text] [Related]
19. Novel heterozygous c.798C>G and c.1040T>G mutations in the GBA1 gene are associated with a severe phenotype of Gaucher disease type 1.
Machaczka M; Klimkowska M
Ann Hematol; 2014 Oct; 93(10):1787-9. PubMed ID: 24577513
[No Abstract] [Full Text] [Related]
20. Imino sugar therapy for type 1 Gaucher disease.
Priestman DA; Platt FM; Dwek RA; Butters TD
Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
[No Abstract] [Full Text] [Related]
[Next] [New Search]
